PP
ALIM

PDT Partners’s Alimera Sciences ALIM Stock Holding History

PDT Partners’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17,723
Closed -$161K – 942
2021
Q2 		$161K Buy
17,723
+5,923
+50% +$58.2K 0.01% 731
2021
Q1 		$114K Buy
+11,800
New +$96.7K 0.01% 736

Other funds holding ALIM

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return

PDT Partners's ALIM Position: Q3 2021 in Review

PDT Partners sold out of Alimera Sciences (ALIM) in Q3 2021, closing a stake of 17,723 shares — an estimated $161K sold.

PDT Partners first reported a position in ALIM in Q1 2021 and held it in 2 quarters. The position peaked at $161K in Q2 2021. 27 funds tracked by Wall St. Rank hold ALIM as of Q3 2021.

  • PDT Partners reported no remaining Alimera Sciences position as of Q3 2021 after selling out during the quarter.
  • PDT Partners sold 17,723 Alimera Sciences shares in Q3 2021, an estimated $161K.
  • PDT Partners first reported a position in Alimera Sciences in Q1 2021 and held it in 2 quarters.
  • PDT Partners's Alimera Sciences position peaked at $161K in Q2 2021.
  • 27 funds tracked by Wall St. Rank held Alimera Sciences as of Q3 2021.

Based on PDT Partners's 13F filing for Q3 2021, filed 15 Nov 2021.